Valuation: Erasca, Inc.

Market Cap 5.04B 4.52B 4.13B 3.77B 7.11B 474B 7.33B 49.8B 19.86B 253B 18.92B 18.51B 798B P/E 2026 *
-14.6x
P/E 2027 * -21.9x
Enterprise Value 4.19B 3.76B 3.44B 3.14B 5.91B 394B 6.1B 41.41B 16.51B 210B 15.73B 15.4B 664B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.04%
Yield 2026 *
-
Yield 2027 * -
1 day+8.59%
1 week+0.42%
Current month+0.42%
1 month+2.05%
3 months-21.73%
6 months+38.56%
Current year+287.37%
1 week 13.11
Extreme 13.11
15.38
1 month 13.1
Extreme 13.1
16.2
Current year 3.36
Extreme 3.36
24.28
1 year 2.21
Extreme 2.21
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.28
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2019
Director of Finance/CFO 43 06/01/2021
Chief Tech/Sci/R&D Officer 66 09/08/2026
Director TitleAgeSince
Chairman 54 30/09/2018
Director/Board Member 79 31/05/2018
Director/Board Member 58 01/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/06/26 Free

Director

29,888 0.0096%
01/04/26 Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
+8.59%+0.42%+534.80%+523.81% 5.04B
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.88%+2.43%+97.75%+219.77% 41.18B
Weighted average by Cap. +0.75%+3.04%+55.84%+170.26%

Financials

2026 *2027 *
Net sales - -
Net income -322M -289M -264M -241M -454M -30.25B -468M -3.18B -1.27B -16.14B -1.21B -1.18B -50.95B -228M -205M -187M -171M -322M -21.45B -332M -2.25B -899M -11.45B -857M -838M -36.13B
Net Debt -849M -761M -696M -635M -1.2B -79.77B -1.23B -8.38B -3.34B -42.56B -3.19B -3.12B -134B -762M -683M -624M -570M -1.07B -71.61B -1.11B -7.53B -3B -38.21B -2.86B -2.8B -121B
Projected Income Statement - Annual - Erasca, Inc.
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
06/11/26 US$14.41 +8.59% 4,032,171
05/11/26 US$13.27 -11.00% 6,689,769
04/11/26 US$14.91 +1.84% 3,501,512
03/11/26 US$14.64 +4.20% 3,798,384
02/11/26 US$14.05 -2.09% 4,428,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Erasca, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.41USD
Average target price
24.11USD
Spread / Average Target
+67.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Erasca, Inc.
  1. Stock Market
  2. Stocks
  3. ERAS Stock